Novartis Puts Down $50m For Mesoblast COVID-19 Cell Therapy
Reversal Of Fortunes For Remestemcel-L
The Australian company's off-the-shelf cell therapy fell foul of the US FDA for graft-versus-host disease recently but Novartis is backing remestemcel-L as a potential treatment for acute respiratory distress syndrome.
